Journal: NPJ Breast Cancer

Article Title: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

doi: 10.1038/s41523-022-00397-y

Figure Lengend Snippet: Clonogenic survival assays indicate concentration-dependent radiosensitization of ER+ MCF-7 cells with tamoxifen ( a ) or fulvestrant ( b ). Radiosensitization was also observed in T47D cells with tamoxifen ( c ) or fulvestrant ( d ) treatment, but not in the ER-negative SUM-159 cells treated with tamoxifen ( e ) or fulvestrant ( f ). Clonogenic survival assays were performed in MCF-7 cells pretreated with CSS for 1 h compared to FBS-treated cells ( g ), or MCF-7 cells pretreated for 3 days with CSS before stimulation with β-estradiol ( h ). Clonogenic treatment times are displayed in a schematic ( i ). Data from three or four replicate experiments are graphed as mean ± SEM. (* P < 0.05; ** P < 0.01; *** P < 0.001; NS = not significant).

Article Snippet: Tamoxifen was obtained from MedChemExpress (HY-13757A).

Techniques: Concentration Assay

Journal: NPJ Breast Cancer

Article Title: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

doi: 10.1038/s41523-022-00397-y

Figure Lengend Snippet: The neutral comet assay was used to assess dsDNA break repair in MCF-7 cells treated with ± 500 nΜ tamoxifen ± 25 nM fulvestrant ± 4 Gy RT ( a ). Representative images of comets are shown. NHEJ efficiency in MCF-7 cells was assessed using a transient pEYFP reporter construct. Cells were treated with tamoxifen ( b ) or fulvestrant ( c ) with AZD7762, a Chk1/2 inhibitor, used as a negative control and NU7441, a DNAPK inhibitor, used as a positive control. Data from triplicate experiments are graphed as mean ± SEM. (* P < 0.05; ** P < 0.01; *** P < 0.001).

Article Snippet: Tamoxifen was obtained from MedChemExpress (HY-13757A).

Techniques: Neutral Comet Assay, Construct, Negative Control, Positive Control

Journal: NPJ Breast Cancer

Article Title: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

doi: 10.1038/s41523-022-00397-y

Figure Lengend Snippet: Immunofluorescence was used to stain Rad51 foci in MCF-7 cells treated with ±500 nM tamoxifen ± 4 Gy RT ( a ) and in T47D cells treated ± 2.0 μM tamoxifen ± 4 Gy RT ( b ). A stable homologous recombination reporter construct was used to assess HR efficiency in MCF-7 cells treated with tamoxifen ( c ). AZD7762, a Chk1/2 inhibitor, was used as a positive control; NU7441, a DNAPK inhibitor, was used as a negative control. Representative images of MCF-7 Rad51 foci at the 6 h timepoint are shown ( d ). Total Rad51 protein levels were assessed by western blot in MCF-7 and T47D cells treated ± tamoxifen ± RT at 6- and 16-h post-RT ( e ). Data from three or four replicate experiments are graphed as mean ± SD. (* P < 0.05; ** P < 0.01; NS = not significant).

Article Snippet: Tamoxifen was obtained from MedChemExpress (HY-13757A).

Techniques: Immunofluorescence, Staining, Homologous Recombination, Construct, Positive Control, Negative Control, Western Blot

Journal: NPJ Breast Cancer

Article Title: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

doi: 10.1038/s41523-022-00397-y

Figure Lengend Snippet: MCF-7 cells were treated with 500 nM tamoxifen or 25 nM fulvestrant for one hour prior to 4 Gy radiation and stained for β-galactosidase at 14 days post-RT. Quantification of cells positive for β-galactosidase was performed for MCF-7 ( a ) and T47D ( c ) cells. Representative images of β-galactosidase staining are shown for each cell line ( b , d ). Data from three or four replicate experiments are graphed as mean ± SD. (* P < 0.05; ** P < 0.01; **** P < 0.0001).

Article Snippet: Tamoxifen was obtained from MedChemExpress (HY-13757A).

Techniques: Staining

Journal: NPJ Breast Cancer

Article Title: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

doi: 10.1038/s41523-022-00397-y

Figure Lengend Snippet: MCF-7 cells were injected into the mammary fat pads of CB17-SCID mice, and treatment was initiated when tumors were 80–100 mm 3 . Mice treated with the combination of tamoxifen and radiation received tamoxifen for 1 or 6 days prior to the start of radiotherapy ( a ). The average change in tumor volume was recorded for each treatment condition ( b ). Time to tumor doubling was assessed for each treatment ( c ). The combination treatment did not have significant toxicity as there were no changes in mouse weights ( d ). Tamoxifen with radiation was found to be synergistic using the fractional tumor volume method in which ratios >1 indicate synergy ( e , f ). Data are graphed as mean ± SEM. (** P < 0.01, *** P < 0.001, **** P < 0.0001).

Article Snippet: Tamoxifen was obtained from MedChemExpress (HY-13757A).

Techniques: Injection

Journal: Balkan medical journal

Article Title: Upregulation of miR-99b-5p Modulates ESR1 Expression as an Adaptive Mechanism to Circumvent Drug Response via Facilitating ER/HER2 Crosstalk.

doi: 10.4274/balkanmedj.galenos.2025.2024-12-47

Figure Lengend Snippet: FIG. 2. Inhibiting miR-99b-5p contributes to tamoxifen or trastuzumab sensitivity in BT-474 cells. Suppression of cell proliferation by miR- 99b-5p inhibitor/drug combinations compared to untreated control cells (n = 3, *p < 0.05, #p < 0.01). Cells were transfected with 100 nM inhibitor for 48 hours then were treated with 10 μM tamoxifen (a) or 6 μg/ml trastuzumab (b). Cells were monitorized for 180 h. TAM and TAM+ miR-99b-5p represented only tamoxifen and tamoxifen with with miR-99b-5p inhibitor, respectively (a). TRAST and TRAST+ miR-99b-5p represented only trastuzumab and trastuzumab with with miR-99b-5p inhibitor, respectively (b).

Article Snippet: Tamoxifen was sourced from TOCRIS (Minneapolis, MN, USA).

Techniques: Control, Transfection

Journal: Balkan medical journal

Article Title: Upregulation of miR-99b-5p Modulates ESR1 Expression as an Adaptive Mechanism to Circumvent Drug Response via Facilitating ER/HER2 Crosstalk.

doi: 10.4274/balkanmedj.galenos.2025.2024-12-47

Figure Lengend Snippet: FIG. 3. Effect of miR-99b-5p on ER-HER crosstalk signaling in BT474 cells. We investigated the effect of miR-99b-5p, tamoxifen, trastuzumab or the combination on ER-HER2 crosstalk signaling in BT-474 cells. Western blotting was performed to analyze ESR1, HER2 and EGFR. Bar graphs indicated relative levels of proteins vs. scrambled control normalized to β-actin (n = 2, *p < 0.05, **p < 0.01). Drug treatments were used at IC50 concentrations. 25 nM miR-99b-5p mimic or scrambled control (scr) concentrations were applied. TAM+ scr and TAM+ 99b represented tamoxifen with scrambled control (scr) and tamoxifen with miR-99b-5p mimic, respectively (a). TRAST+ scr and TRAST+ 99b represented trastuzumab with scrambled control (scr) and trastuzumab with miR-99b-5p mimic, respectively (b). (c) ESR1 expression in miR-99b-5p mimic-transfected samples was assessed at the RNA level under the treatment conditions of tamoxifen or trastuzumab (*p < 0.01). (d) ESR1 expression was evaluated at the RNA level in the presence of both miR-99b-5p mimic and inhibitor, with a decrease in ESR1 expression observed in samples transfected with the miR-99b-5p inhibitor (*p < 0.01). (e) Western blot analysis of ESR1 was conducted using cytoplasmic and nuclear extracts from BT-474 cells transfected with either a scrambled control, miR-99b-5p mimic, or inhibitor. ER, estrogen receptor; EGFR, epidermal growth factor receptor.

Article Snippet: Tamoxifen was sourced from TOCRIS (Minneapolis, MN, USA).

Techniques: Western Blot, Control, Expressing, Transfection

Journal: Cell Reports Medicine

Article Title: CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer

doi: 10.1016/j.xcrm.2025.102053

Figure Lengend Snippet:

Article Snippet: Tamoxifen citrate , MedChemExpress , Cat# HY-13757.

Techniques: Recombinant, Red Blood Cell Lysis, Sequencing, Software, RNA sequencing